Stock APGE APOGEE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Apogee Therapeutics, Inc. Stock

Equities

APGE

US03770N1019

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
50.3 USD +2.65% Intraday chart for Apogee Therapeutics, Inc. +1.06% +80.03%
Mar. 25 Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease and Other Inflammatory Diseases CI
Mar. 18 Apogee Therapeutics, Inc.(NasdaqGM:APGE) added to S&P Biotechnology Select Industry Index CI

Financials (USD)

Sales 2024 * - Sales 2025 * - Capitalization 2.84B
Net income 2024 * -140M Net income 2025 * -187M EV / Sales 2024 * -
Net cash position 2024 * 288M Net cash position 2025 * 462M EV / Sales 2025 * -
P/E ratio 2024 *
-19.8 x
P/E ratio 2025 *
-16.4 x
Employees 91
Yield 2024 *
-
Yield 2025 *
-
Free-Float 79.21%
More Fundamentals * Assessed data

Chart Apogee Therapeutics, Inc.

Dynamic Chart

Latest news about Apogee Therapeutics, Inc.

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease and Other Inflammatory Diseases CI
Apogee Therapeutics, Inc.(NasdaqGM:APGE) added to S&P Biotechnology Select Industry Index CI
Apogee Closes $483 million Upsized Stock Offering MT
Apogee Therapeutics Prices Upsized $420 Million Share Offering MT
Sector Update: Health Care Stocks Advance Wednesday Afternoon MT
Apogee Therapeutics Shares Rise After Jefferies Raises Price Target MT
Jefferies Adjusts Price Target on Apogee Therapeutics to $75 From $37, Maintains Buy Rating MT
Apogee Therapeutics Unveils $350 Million Share Offering MT
Sector Update: Health Care Stocks Retreating Late Afternoon MT
Sector Update: Health Care Stocks Lower Tuesday Afternoon MT
Top Midday Gainers MT
Sector Update: Health Care MT
Apogee Therapeutics Shares Surge After Phase 1 Atopic Dermatitis Trial Data, Wedbush Price Target Raise MT
Apogee Therapeutics Says Phase 1 Study of Atopic Dermatitis Drug Candidate Exceeds Objectives MT
Wedbush Raises Apogee Therapeutics' PT to $87 From $40 After Reporting Initial Safety, PK Results From Phase 1 Trial of APG777; Maintains Outperform Rating MT
More news

Analyst Recommendations on Apogee Therapeutics, Inc.

Jefferies Adjusts Price Target on Apogee Therapeutics to $75 From $37, Maintains Buy Rating MT
Wedbush Raises Apogee Therapeutics' PT to $87 From $40 After Reporting Initial Safety, PK Results From Phase 1 Trial of APG777; Maintains Outperform Rating MT
Guggenheim Adjusts Apogee Therapeutics' Price Target to $44 From $29, Maintains Buy Rating MT
BTIG Initiates Apogee Therapeutics With Buy Rating, Price Target is $43 MT
TD Cowen Initiates Apogee Therapeutics With Outperform Rating MT
More recommendations

Press releases Apogee Therapeutics, Inc.

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases AQ
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million AQ
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering AQ
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering AQ
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results AQ
More press releases

Quotes and Performance

1 day+2.65%
1 week+1.06%
1 month-24.30%
3 months+50.15%
6 months+192.78%
Current year+80.03%
More quotes

Highs and lows

1 week
43.61
Extreme 43.605
51.01
1 month
43.61
Extreme 43.605
66.80
Current year
27.05
Extreme 27.05
72.29
1 year
14.19
Extreme 14.19
72.29
3 years
14.19
Extreme 14.19
72.29
5 years
14.19
Extreme 14.19
72.29
10 years
14.19
Extreme 14.19
72.29
More quotes

ETFs positioned on Apogee Therapeutics, Inc.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +1.51% -
More ETFs positioned on Apogee Therapeutics, Inc.

Quotes

Date Price Change Volume
24-04-30 50.3 +2.65% 397,405
24-04-29 49 +3.97% 207,028
24-04-26 47.13 +2.77% 238,494
24-04-25 45.86 -1.46% 317,725
24-04-24 46.54 -6.49% 283,432

Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm EDT

More quotes

Company Profile

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Sector
Biotechnology & Medical Research
Calendar
2024-06-04 - Annual General Meeting
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
50.3 USD
Average target price
85.8 USD
Spread / Average Target
+70.58%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
APOGEE THERAPEUTICS, INC. Stock Apogee Therapeutics, Inc.
+80.03% 2.84B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.17% 42.19B
MODERNA, INC. Stock Moderna, Inc.
+10.92% 42.24B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.23% 24.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.79% 18.2B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.69% 12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.13% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.57% 10.4B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. APGE Stock